Cyclacel Pharmaceuticals, Inc. (CYCC)
| Market Cap | 11.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.27M |
| Shares Out | 12.54M |
| EPS (ttm) | -1.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3 |
| Open | 0.907 |
| Previous Close | 0.920 |
| Day's Range | 0.907 - 0.960 |
| 52-Week Range | 0.530 - 3.990 |
| Beta | 1.06 |
| Analysts | Buy |
| Price Target | 16.58 (+1,645.26%) |
| Earnings Date | Mar 27, 2023 |
About CYCC
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced le... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for CYCC stock is "Buy." The 12-month stock price forecast is $16.58, which is an increase of 1,645.26% from the latest price.
News
Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference
BERKELEY HEIGHTS, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...
Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023
– Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral Fadraciclib –
Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
BERKELEY HEIGHTS, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...
Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
- Oral Fadraciclib Daily Dosing Well Tolerated in 18 Evaluable Patients Treated in Dose-Escalation of Phase 1/2 Trial in Advanced Solid Tumors and Lymphoma -
Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results
BERKELEY HEIGHTS, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...
Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients Daily dosing of fadraciclib was well tolerated; s...
Cyclacel Hosting Research & Development Day
-Program Update on its CDK2/9 Inhibitor, Oral Fadraciclib, and Oral PLK1 Inhibitor, CYC140, for the Treatment of Advanced Solid Tumors and Lymphoma-
Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium
- Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma - - Preliminary Dose Escalation Data to be Presented on Novel CDK2/9...
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference
BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative ...
Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
- Oral fadraciclib demonstrated good tolerability with continuous dosing; anticipate entering Phase 2 POC stage in 2H 2022 –
Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results
BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...
Cyclacel To Test Higher Doses Of Fadraciclib In Solid Tumor Patients
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) is adding two dose levels in a protocol amendment to test higher doses of oral fadraciclib before determining the recommended Phase 2 dose anticipated in 2H...
Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline
- Completed Enrollment in Phase 1 Dose Escalation with Oral Fadraciclib in Solid Tumors -
Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D.
BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...
Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results
BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas
- CYC140, a Potent and Selective PLK1 Inhibitor to Be Evaluated as a Single Agent Across Multiple Solid Tumor and Lymphoma Types in Streamlined, Registration-Directed Study - - CYC140, a Potent and Se...
Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia
-New Preclinical Data Highlight Fadraciclib's Apoptosis Enabling Mechanism in Leukemia-
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
-Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First Half of 2022 –
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results
BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative ...
Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference
BERKELEY HEIGHTS, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...
Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022
– Now Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib –
Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference
BERKELEY HEIGHTS, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes
Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated as a Single Agent and in Combinations in Streamlined, Registration-Directed Study Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evalua...
Cyclacel Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Business Update
BERKELEY HEIGHTS, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...
Cyclacel Pharmaceuticals Presenting at Three Conferences in September
BERKELEY HEIGHTS, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative ...